Transcatheter or Surgical Aortic Valve Replacement in Patients with Severe Aortic Stenosis and Small Aortic Annulus: A Randomized Clinical Trial.

Josep Rodés-Cabau, MD, PhD[1], Henrique Ribeiro, MD, PhD[2], Siamak Mohammadi, MD[1], Vicenç Serra, MD[3], Talal Al-Atassi, MD[4], Andres Iniguez, MD[5], Victoria Vilalta, MD, PhD[6], Luis Nombela-Franco, MD, PhD[7], Jose Ignacio Saez de Ibarra, MD[8], Vincent Auffret, MD, PhD[9], Jessica Forcillo, MD[10], Lenard Conradi, MD[11], Marina Urena, MD, PhD[12], Cesar Moris, MD, PhD[13], Antonio Muñoz-Garcia, MD, PhD[14], Jean-Michel Paradis, MD[1], Eric Dumont, MD[1], Dimitri Kalavrouziotis, MD[1], Pablo Maria Pomerantzeff, MD, PhD[2], Vitor Emer Egypto Rosa, MD, PhD[2], Mariana Pezzute Lopes, MD[2], Carles Sureda, MD[3], Victor Alfonso Jimenez Diaz, MD[5], Carlos Giuliani, MD[1], Marisa Avvedimento, MD[1], Emilie Pelletier-Beaumont, MSc[1], Philippe Pibarot, PhD[1], on behalf of the VIVA trial investigators.

[1]Quebec Heart & Lung Institute, Laval University, Quebec City, Canada
[2]INCOR, Sao Paulo, Brasil
[3]Hospital Universitari Vall d'Hebron, Barcelona, Spain
[4]Ottawa Heart Institute, Ottawa, Canada
[5]Hospital Alvaro Cunqueiro, Vigo, Spain
[6]Hospital Germans Tries i Pujol, Badalona, Spain
[7]Hospital Clínico San Carlos, Madrid, Spain
[8]Hospital Son Espases, Mallorca, Spain
[9]Centre Hospitalier Universitaire de Rennes, Rennes, France
[10]Centre Hospitalier Universitaire de Montreal, Montreal, Canada
[11]University Heart Center, Hamburg, Germany
[12]Bichat Hospital, Paris, France
[13]Hospital Central de Asturias, Oviedo, Spain
[14]Hospital Virgen de la Victoria, Malaga, Spain

Short title: TAVR vs. SAVR in Small Aortic Annulus Patients

Word count: 3174

Address for correspondence:

Josep Rodés-Cabau, MD, PhD
Quebec Heart and Lung Institute, Laval University
Quebec City, QC, Canada
Tel : 418-656-8711; FAX : 418-656-4544; E-mail: josep.rodes@criucpq.ulaval.ca

ABSTRACT

BACKGROUND. The optimal treatment in patients with severe aortic stenosis (AS) and small aortic annulus (SAA) remains to be determined. The objectives of this study were to compare the hemodynamic and clinical outcomes between transcatheter aortic valve replacement (TAVR) and surgical aortic valve replacement (SAVR) in patients with a SAA.

METHODS. Prospective multicenter international randomized trial performed in 15 university hospitals. Participants were 151 patients with severe AS and SAA (mean diameter <23 mm) were randomized (1:1) to TAVR (n=77) vs SAVR (n=74), The primary outcome was impaired valve hemodynamics (i.e. severe prosthesis patient mismatch [PPM] or moderate-severe aortic regurgitation [AR]) at 60 days as evaluated by Doppler-echocardiography and analyzed in a central echocardiography core laboratory. Clinical events were secondary outcomes.

RESULTS. The mean age of the participants was 75±5 years, with 93% of women, a median STS of 2.5 (1.7-3.3)%, and a mean annulus diameter of 21.1±1.2 mm.. There were no differences between groups regarding mortality (TAVR:1.3%, SAVR:1.4%, p=1.0) and stroke (TAVR:0%, SAVR:2.7%, p=0.239) at 30 days. The rate of severe PPM or moderate-severe AR was similar in both groups (TAVR:5.6%, SAVR:10.3%, p=0.298), with no differences between groups in the incidence of severe PPM (5.6% vs. 10.3%, p=0.298) and moderate-severe AR (0% in both groups). After a median follow-up of 2 (1-4) years, there were no differences between groups regarding mortality (TAVR:9.1%, SAVR:8.1%, p=1.0), stroke (TAVR:3.9%, SAVR:4.1%, p=1.0), and cardiac hospitalization (TAVR:19.5%, SAVR:20.3%, p=1.0).

CONCLUSIONS. In patients with severe AS and SAA (women in the vast majority), TAVR and SAVR provided similar valve hemodynamic results. After a median follow-up of 2 years, there were no differences in clinical outcomes between groups. The results of this trial suggest

that these 2 therapies represent a valid alternative for treating patients with SA and SAA, and treatment selection should likely be individualized according to baseline characteristics, additional anatomical risk factors, and patient preference.

TRIAL REGISTRATION. Clinicaltrials.gov: NCT03383445

Key words: transcatheter aortic valve implantation, aortic stenosis, prosthesis-patient mismatch

INTRODUCTION

Degenerative aortic stenosis (AS) remains the most common valvular disorder affecting western countries. A significant proportion of AS patients harbor a small aortic annulus (SAA), particularly among the women population.[1] The treatment of this group of patients remains challenging, with a higher incidence of suboptimal hemodynamic results and its potential deleterious clinical impact following aortic valve replacemen.[1-3] In the last decade, transcatheter aortic valve replacement (TAVR) has become an effective alternative to surgical aortic valve replacement (SAVR) for the treatment of AS. Current guidelines recommend both treatment options for treating elderly patients with AS, but with a preference for SAVR as a default option in younger and lower risk patients.[4,5] However, aortic annular size, prosthetic valve hemodynamic results, and gender factors are not taken into consideration in current guideline recommendations.

Data from observational studies and sub-studies from randomized trials suggest superior prosthetic valve hemodynamics following TAVR (vs. SAVR) in patients with SAA.[6-8] Additionally, several studies have reported improved outcomes associated with TAVR in women and patients of Asian descent,[9-12] both of which constitute populations with a high prevalence of SAA. However, women have often been largely under-represented in heart valve trials,[13] and no randomized studies exist regarding the optimal treatment of women with severe AS and SAA. The objective of this multicenter randomized trial was to compare the hemodynamic and clinical outcomes of TAVR vs. SAVR for the treatment of patients with AS and SAA.

METHODS

Trial design and patients. The VIVA trial (Clinicaltrials.gov: NCT03383445) was a prospective randomized controlled trial (investigator initiated). The study was conducted in 15 centers in Canada, Europe, and Brazil, and included elderly (≥65 years old) patients with severe AS and SAA considered eligible for either SAVR or TAVR by the multidisciplinary heart team of each participating center. Exclusion criteria included the presence of aortic root dilatation >45 mm, coronary artery disease not treatable by percutaneous coronary intervention or coronary artery bypass grafting, SYNTAX score >32, significant concomitant mitral or tricuspid valve disease, or prior aortic valve surgery. Patients were initially screened on the basis of an aortic annulus diameter <21 mm as evaluated by transthoracic echocardiography, and the final inclusion of the patient was based on the presence of a mean aortic annular diameter <23 mm and a minimal diameter ≤21.5 mm as evaluated by contrast computed tomography (CT). Severe aortic stenosis was defined as (i) a jet velocity ≥ 4.0 m/s or mean gradient ≥ 40 mmHg or velocity ratio <0.25, and aortic valve area ≤ 1.0 cm^2 or aortic valve area index ≤ 0.6 cm^2/m^2; or (ii) mean gradient >30 mmHg and aortic valve area ≤ 1.0 cm^2 or aortic valve area index ≤ 0.6 cm^2/m^2, and >1200 Agatston units for women or >2000 Agatston units for men as determined by non-contrast CT. The study was approved by the Ethics Committee of each participating center, and all patients provided signed informed consent for participating in the trial (trial protocol, including the changes in inclusion criteria and reasons, are reported as Supplemental material).

Patients were randomly assigned in a 1:1 ratio to receive TAVR or SAVR. Random block sizes of 10 were used to conceal treatment allocation and implementation was assessed by an independent statistician (not related to the study). Randomization was centralized, and performed

using the electronic case-report form (eCRF) system. Participants and site staff were unblinded to the treatment assigned.

Study procedures. The TAVR procedures were performed according to routine clinical practice in each participating center, and only newer generation valve systems were used in the study, including the balloon-expandable SAPIEN 3/ULTRA valve (Edwards Lifesciences, Irvine, CA), and the self-expandable Evolut R/PRO/PRO+ valve (Medtronic, Minneapolis, MN), and the Acurate Neo/Neo2 valve (Boston Scientific, Boston, MA). Prosthesis valve sizing was based on CT measurements and followed the recommendations from the manufacturers. The SAVR procedures were performed according to the standards of the surgical team of each participating center, and all surgical prosthetic valves approved for clinical use were allowed in the study. Also, the decision regarding aortic root enlargement was left to the criteria of the surgeon responsible for the intervention.

Outcomes. The primary efficacy outcome was impaired valve hemodynamics defined as the occurrence of severe prosthesis-patient mismatch (PPM) and/or moderate-severe aortic regurgitation (AR) as evaluated by Doppler-echocardiography at 60 days. Secondary end points included the mean transvalvular gradient at 60 days, and clinical endpoints (death, stroke, major or life-threatening bleeding, new-onset atrial fibrillation, permanent pacemaker implantation, cardiac rehospitalization) at 30 days and at follow-up. Patients were followed at 30, 60 days, 1 year, and yearly thereafter up to 5 years. Clinical events were defined according to VARC-2 criteria (14). The functional status (NYHA class) and quality of life (as determined by the Kansas City Cardiomyopathy Questionnaire [KCCQ]) were evaluated at baseline and at each follow-up visit. There were no changes to trial outcomes after the trial commenced.

Echocardiographic findings (for echocardiography examinations at 60 days post-intervention) were evaluated in a central Echocardiography Core Laboratory (Core Lab of the Quebec Heart & Lung Institute, Quebec City, Canada), blinded to the allocated treatment. Severe PPM was defined per-protocol as an indexed effective orifice area (EOA) ≤0.65 cm^2/m^2 (14). Severe PPM was also assessed according to VARC-3 criteria, defined as an indexed EOA ≤0.65 cm^2/m^2 for patients with BMI <30 kg/m^2 and as an indexed EOA ≤0.55 cm^2/m^2 for patient with BMI ≥30 kg/m^2 (15).

Statistical analysis. Based on the results of a sub-study from the PARTNER 1 trial (7), the expected rate of severe PPM in the TAVR group was evaluated at 19%, with a rate of moderate-severe AR of 3% (overall incidence of the primary endpoint of 22%). In the surgical group, the expected rate of severe PPM was estimated at 38%, without any anticipated moderate-severe AR (7). A total of 130 patients per group were calculated to provide 80% power to detect significant differences in the composite rate of PPM or moderate-severe AR between groups with a p value <0.05, and the final sample size of the study was estimated at 300 patients (150 patients per group). The study started in August 2017, with a progressive inclusion of participating centers within the 1st two years of the study. Once all centers were activated and enrolling patients, the COVID-19 pandemic appeared and this translated into a drastic reduction in the enrollment rate in all centers. Additionally, the results of 2 randomized trials showing the non-inferiority or superiority of TAVR for treating aortic stenosis in elderly patients were published during the execution of the study (16, 17), further impending the enrolment of patients after the COVID-19 pandemic. It was finally decided to prematurely stop study enrolment in April 2023, when 156 patients (52% of the estimated sample size) had been included in the study.

The primary and secondary end point analyses were performed on an intention-to-treat basis. A secondary "as treated" analysis including only those patients who finally received the allocated treatment was also performed. Qualitative variables were expressed as percentages and quantitative variables as mean (standard deviation) or median (interquartile range) depending on variable distribution. Comparison of numerical variables was performed using the Student´s t test or Wilcoxon rank sum test. Survival curves for time-to-event variables were performed using Kaplan-Meier estimates, and the log rank test was used for group comparisons. Event rates of clinical events at 30 days and at follow-up were summarized as mean difference (95% CI). A p value <0.05 was considered significant. The analyses were performed with SAS (version 9.4).

RESULTS

The flowchart of the study population is shown in **Supplemental Figure 1**. A total of 156 patients were randomized, and 79 and 77 patients were allocated to TAVR and SAVR, respectively. Of these, 5 patients were excluded (consent withdrawn before treatment=2; intended use of a transcatheter valve non-approved for the study=1; significant mitral regurgitation requiring surgical intervention=1; not eligibility for the study after second CT evaluation=1), and a total of 77 and 74 patients were finally included in the TAVR and SAVR groups, respectively. All patients but 1 received the allocated treatment in the TAVR group (1 patient in the TAVR group finally underwent SAVR), and 2 patients in the SAVR group finally had a TAVR procedure (these 3 patients remained in the study and were included in the allocated groups for the intention-to-treat analyses).

The main baseline and procedural characteristics of the study population are shown in **Table 1**. The mean age and median STS of the study population were 75.5 (5.0) years and 2.5

(1.67-3.28) %, respectively, and the vast majority of patients (93%) were women. The mean and minimal aortic annular diameters as evaluated by CT were of 21.1 (1.2) mm and 18.6 (1.5) mm, respectively.

In the TAVR group, 31 (40.8%) and 45 (59.2%) patients received a balloon- and self-expandable valve system, respectively, and the median valve size was of 23 (IQR: 23-26) mm. In the SAVR group, all patients but one (aortic valve repair) received a bioprosthetic valve, and the median valve size was of 21 (IQR: 21-21) mm. The types and sizes of transcatheter and surgical valves implanted in the study are shown in **Supplemental Table 1.**

30-day clinical outcomes. There were no differences between groups regarding mortality (TAVR: 1.3%, SAVR: 1.4%, mean difference: 0.05%, 95% CI: -6.3 to 5.9%, p=1.000) or stroke (TAVR: 0%, SAVR: 2.7%, mean difference: -2.7%, 95% CI: -9.4 to 2.3%, p=0.239) at 30 days, whereas major or life-threatening bleeding occurred in 7.8% and 21.6% of patients in the TAVR and SAVR groups, respectively (mean difference: -13.8%, 95% CI: -26.0 to -2.1%, p=0.021), and new-onset atrial fibrillation in 6.5% and 27.0% of TAVR and SAVR patients, respectively (mean difference: -20.5%, 95% CI: -32.8 to -7.3 %, p=<0.001) (**Table 2**). There were no differences between groups in incidence of permanent pacemaker implantation at 30 days (TAVR: 11.7%, SAVR: 5.4%, mean difference: 6.3%, 95% CI: -3.1 to 16.3%, p=0.247). The median hospitalization time was shorter in the TAVR group (3 [2-6] days vs. 8 [6-11] days, mean difference: -6, 95% CI: -8 to -3, p<0.001).

Valve hemodynamic outcomes at 60 days. A total of 143 patients had an echocardiographic examination at 60 days. In addition, the echocardiographic examinations of 5 patients (3 and 2 patients in the TAVR and SAVR groups, respectively) who had an echocardiography at hospital discharge but not at 60 days (due to pandemic restrictions) were waived to be included in the

final echo centralized analyses. The main echocardiographic results at 60 days are shown in **Table 3**. There were no differences in mean and maximal transvalvular gradient values between groups (TAVR: 11±5 mmHg, SAVR: 11±5 mmHg for mean gradient, mean difference: 0.3, 95% CI: -1.3 to 1.9, p=0.704; TAVR: 22±9 mmHg, SAVR: 21±9 mmHg for maximal gradient, mean difference: 0.7, 95% CI: -2.2 to 3.6, p=0.653). The rate of patients with a residual mean gradient >20 mmHg was similar in both groups (TAVR: 5.4%, SAVR: 9.6%, mean difference: -5.0, 95% CI: -13.8 to 3.9, p=0.458).

The rate of severe PPM or moderate-severe AR (*primary endpoint*) was similar in both groups (TAVR: 5.6%, SAVR: 10.3%, mean difference: -4.7, 95% CI: -13.2 to 4.2, p=0.298), with no differences between groups in the incidence of severe PPM (TAVR: 5.6%, SAVR: 10.3%, mean difference: -4.7, 95% CI: -13.2 to 4.2, p= 0.298) and moderate-severe AR (TAVR: 0%, SAVR: 0%). The lack of significant differences between groups persisted when applying the VARC-3 definition for severe PPM (TAVR: 4.2%, SAVR: 7.4%, mean difference: -3.2, 95% CI: -10.9 to 4.6, p= 0.485).

Late follow-up outcomes. The median follow-up of the study population was of 2 (1-4) years, with no patient lost to follow-up. The main clinical events at follow-up according to treatment allocation are shown in **Table 2.** The time-to-event curves at 2-year follow-up for mortality, stroke, cardiac rehospitalization, and the combined endpoint are shown in **Figure 1.** There were no differences between groups in cardiac events at follow-up. Most deaths in both groups were of cardiac cause (61%), and most cardiac rehospitalization events were related to heart failure events (n=10, 33% of total cardiac rehospitalization events).

The changes in NYHA class and quality of life over time according to treatment allocation are shown in **Figure 2**. TAVR patients exhibited a more rapid improvement in

functional class and quality of life, as shown by significant differences with SAVR patients at 30 days, but these differences disappeared at 1- and 2-year follow-up. The changes in valve hemodynamic parameters (mean gradient, aortic valve area) over time are shown in **Figure 2.**

"As-treated" analyses. The baseline and procedural characteristics of those patients that finally received the allocated treatment are shown in **Supplemental Table 2.** The valve hemodynamic outcomes at 60 days according to treatment allocation are shown in **Supplemental Table 3.** The results remained similar to the intention-to-treat analyses.

DISCUSSION

The VIVA trial is the first randomized trial in the field of AS field dedicated to SAA patients, including a vast majority (93%) of women. The main findings of the study can be summarized as follows: (i) TAVR and SAVR using contemporary bioprosthetic valves were associated with similar valve hemodynamic outcomes at 60 days, with no significant changes in transvalvular gradient or aortic valve area up to 2-year follow-up, (ii) there were no differences between groups in 30-day clinical outcomes, except for a higher rate of major/life-threatening bleeding and atrial arrhythmias in the SAVR group, (iii) TAVR and SAVR exhibited similar clinical outcomes including mortality, stroke, and cardiac rehospitalization events at 2-year follow-up.

The strict anatomical criteria applied in a prospective manner and using CT parameters in this trial translated into the inclusion of a population with true SAA, including a mean aortic annulus diameter and area of ~21 mm and <350 mm^2, respectively. Also, this anatomical feature presented a clear sex-related association, with the vast majority of patients being women, and this was in accordance with prior studies including AS patients with SAA.[1,18,19] This could be

largely explained by the small BSA in women compared to men,[20] but specific sex-specific differences beyond BSA parameters cannot be excluded.

Most patients included in the VIVA trial exhibited a low surgical risk, and there were no differences in early mortality or stroke events between groups. Despite the presence of a slightly older age and higher surgical risk, the 30-day outcomes were similar to those obtained in low-risk TAVR vs. SAVR trials that included a minority (about one third) of women.[16,17] Also, in accordance with such randomized trials, SAVR was associated with a higher risk of some periprocedural complications like bleeding and new-onset atrial fibrillation, but TAVR candidates tended to exhibit higher rates of conduction disturbances. Some previous studies reported worse clinical outcomes in women (vs. men) undergoing SAVR, including higher mortality rates and a higher incidence of periprocedural complications.[21,22] Indeed, some studies including a recent meta-analysis showed improved outcomes with TAVR (vs. SAVR) at early and midterm follow-up among women.[23-25] The results of the VIVA trial showed similar clinical outcomes in TAVR and SAVR groups after a median follow-up of 2 years, with all-cause mortality and cardiac rehospitalization rates of 8.6% and 20.2%, respectively, in the overall cohort. The 2-year mortality rate appears to be slightly higher than the <5% reported in the PARTNER 3 and Evolut Low Risk trials.[26,27] This may be partially related to the slightly higher surgical risk and older age of the patients included in the VIVA trial, but specific factors related to this population of women with SAA cannot be excluded. Also, the PARTNER 3 and Evolut Low Risk trials showed a lower rehospitalization rate at 2 years in the TAVR (vs. SAVR) group,[26,27] and these results were not reproduced in our trial. The results of the ongoing REIA trial (NCT04160130), comparing the 1-year clinical outcomes of TAVR vs. SAVR in women patients will provide definitive data on this issue.

Unlike prior non-randomized studies in AS patients with SAA (7,8), the VIVA trial showed similar prosthetic valve hemodynamic results of TAVR compared to SAVR, with no differences in the rate of severe PPM and mean transvalvular gradients of 11 mmHg in both groups. In fact, the incidence of severe PPM was much lower than expected in the SAVR group compared with prior sub-studies from randomized trials reporting an incidence close to 40% among SAA candidates.[7,8] Interestingly, this relatively low PPM rate in such a challenging population (with mean and minimal aortic annulus diameters of 21 and 18 mm, respectively) was achieved despite a relatively limited use of aortic root enlargement maneuvers (about 1 out of 10 patients), a well-established surgical strategy for preventing PPM and improving valve hemodynamic results in patients with SAA.[1,28] The reasons for such results are likely multifactorial. Some studies have shown the usefulness of CT examinations prior to SAVR in order to improve the planning of the surgical intervention.[29,30] The cardiac surgeons involved in the VIVA trial had systematic access to a pre-procedural cardiac CT, with accurate measurements of the aortic annulus in all patients, and this may have positively influenced the surgical strategy, such as optimized selection of prosthetic valve sizes ideally suited to the patient's annulus. Also, sutureless valves were used in a high proportion of patients, and some studies have shown improved hemodynamic results with this type of surgical valve, particularly in patients with SAA.[31] Although most patients undergoing SAVR had a stented bioprosthesis, the vast majority received a recent valve generation, with superior hemodynamic performance compared to prior valve generations.[32-34] Finally, most prior studies used pre-discharge echocardiography data to evaluate valve hemodynamics after SAVR.[1] At pre-discharge, the echocardiograms are frequently of suboptimal quality due to limited acoustic window post-SAVR, and are often performed in hyperdynamic conditions (secondary to periprocedural

inflammation, anemia, or arrhythmias). This was the reason for a delayed (60-day) echocardiography evaluation in our study, as recommended by guidelines.[35]

In the TAVR group, there was a similar distribution of balloon- and self-expandable valves, which reflects current practice standards in most western countries. The rate of severe PPM in this group was also lower than initially expected, but similar to other studies using newer generation transcatheter valve systems.[19] Some observational studies have shown improved hemodynamic results associated with the use of self-expandable valves, particularly those with a supra-annular valve like the ones used in our study, but this failed to translate into improved clinical outcomes.[18,19,36] The ongoing SMART trial (NCT03383445), comparing TAVR with the (balloon-expandable) SAPIEN 3 vs. the (self-expandable) Evolut valve systems for the treatment of SAA patients will likely shed more light on this topic.

Limitations. The sample size of the study was limited and the possibility of a type II error for some clinical variables cannot be excluded. Also, there was no clinical event adjudication committee for this trial. The early termination of the trial could have impacted the primary endpoint results of the study. However, no evident numerical tendency was observed regarding the possible superiority of one group vs. the other after the inclusion of half of the study population, and similar results regarding valve hemodynamics would have been likely obtained even after including the initial estimated sample size (300 patients), particularly due to the much lower than expected rate of severe PPM among SAVR recipients.

Conclusions. The vast majority of low-to-intermediate risk AS patients exhibiting the anatomic feature of SAA were women. In this challenging population, TAVR and SAVR

provided similar valve hemodynamic outcomes as evaluated by Doppler echocardiography, with relatively low rates of severe PPM in both groups. Also, TAVR and SAVR were associated with similar early and late (2-year) clinical outcomes. The results of this trial suggest that these 2 therapies represent a valid alternative for treating patients with SA and SAA, and treatment selection should likely be individualized according to baseline characteristics, additional anatomical risk factors, and patient preference.

ACKNOWLEDGMENTS

Dr. Rodés-Cabau holds the Research Chair "Fondation Famille Jacques Larivière" for the Development of Structural Heart Disease Interventions (Laval University, Quebec City, Canada).

FUNDING

Investigator initiated trial, with financial support from the Research Chair "Fondation Famille Jacques Larivière" for the Development of Structural Heart Disease Interventions (Laval University, Quebec City, Canada); grant from the Foundation of the Quebec Heart & Lung Institute (Quebec City, Canada); and grant from the Research Center of the Quebec Heart & Lung Institute (Quebec City, Canada).

CONFLICT OF INTEREST

Dr. Rodés-Cabau has received institutional research grants from and is consultant for Edwards Lifesciences and Medtronic. Dr. Nombela-Franco has received consulting fees from Edwards Lifesciences. Dr Conradi is a member of the Advisory Board of Medtronic, Abbott, JenaValve, and Neovase; and has received consulting fees from Edwards Lifesciences, Boston Scientific, New Valve Technology, and MicroInterventions. Dr Moris received fees as a proctor from Medtronic and Boston Scientific. Pibarot has received institutional research grants from Edwards Lifesciences, Medtronic, Pi-Cardia, and Novartis. The rest of authors do not report any significant conflict of interest with respect to the content of this article.

REFERENCES

1. Freitas-Ferraz AB, Tirado-Conte G, Dagenais F, et al. Aortic stenosis and small aortic annulus. *Circulation.* 2019;139:2685–2702.

2. Head SJ, Mokhles MM, Osnabrugge RLJ, et al. The impact of prosthesis-patient mismatch on long-term survival after aortic valve replacement: a systematic review and meta-analysis of 34 observational studies comprising 27,186 patients with 133,141 patient-years. *Eur Heart J.* 2012;33:1518–1529.

3. Dayan V, Vignolo G, Soca G, Paganini JJ, Brusich D, Pibarot P. Predictors and outcomes of prosthesis-patient mismatch after aortic valve replacement. *J Am Coll Cardiov Imag.* 2016;9:924–933.

4. Otto CM, Nishimura RA, Bonow RO, et al. 2020 ACC/AHA Guidelines for the management of patients with valvular heart disease: a report of the American College of Cardiology/American Heart Association Joint Committee on clinical practice guidelines. *J Am Coll Cardiol.* 2021;77:450–500.

5. Vahanian A, Beyersdorf F, Praz F, et al. 2021 ESC/EACTS Guidelines for the management of valvular heart disease. *Eur Heart J*. 2022;43:561–632.

6. Clavel M-A, Webb JG, Pibarot P, et al. Comparison of the hemodynamic performance of percutaneous and surgical bioprostheses for the treatment of severe aortic stenosis. *J Am Coll Cardiol*. 2009;53:1883–1891.

7. Rodés-Cabau J, Pibarot P, Suri RM, et al. Impact of aortic annulus size on valve hemodynamics and clinical outcomes after transcatheter and surgical aortic valve replacement: insights from the PARTNER Trial. *Circ Cardiovasc Interv.* 2014;7:701–711.

8. Deeb GM, Chetcuti SJ, Yakubov SJ, et al. Impact of Annular Size on Outcomes After Surgical

or Transcatheter Aortic Valve Replacement. *Ann Thorac Surg.* 2018;105:1129–1136.

9. Humphries KH, Toggweiler S, Rodés-Cabau J, et al. Sex differences in mortality after transcatheter aortic valve replacement for severe aortic stenosis. *J Am Coll Cardiol*. 2012;60:882–886.

10. O'Connor SA, Morice M-C, Gilard M, et al. Revisiting sex equality with transcatheter aortic valve replacement outcomes: a collaborative, patient-level meta-analysis of 11,310 patients. *J Am Coll Cardiol.* 2015;66:221–228.

11. Kodali S, Williams MR, Doshi D, et al. Sex-specific differences at presentation and outcomes among patients undergoing transcatheter aortic valve replacement: a cohort study. *Ann Intern Med.* 2016;164:377–384.

12. Yoon S-H, Ahn J-M, Hayashida K, et al. Clinical outcomes following transcatheter aortic valve replacement in Asian population. *J Am Coll Cardiol Intv*. 2016;9:926–933.

13. Reddy KP, Faggioni M, Eberly LA, et al. Enrollment of older patients, women, and racial and ethnic minority individuals in valvular heart disease clinical trials: a systematic review. *JAMA Cardiol.* 2023

14. Kappetein AP, Head SJ, Généreux P, et al. Updated standardized endpoint definitions for transcatheter aortic valve implantation: the Valve Academic Research Consortium-2 consensus document. *Eur Heart J*. 2012;33:2403–2418.

15. Généreux P, Piazza N, Alu MC, et al. Valve Academic Research Consortium 3: updated endpoint definitions for aortic valve clinical research. *J Am Coll Cardiol.* 2021;77:2717–2746.

16. Mack MJ, Leon MB, Thourani VH, et al. Transcatheter aortic-valve replacement with a balloon-expandable valve in low-risk patients. *N Engl J Med.* 2019;380:1695–1705.

17. Popma JJ, Deeb GM, Yakubov SJ, et al. Transcatheter aortic-valve replacement with a self-

expanding valve in low-risk patients. *N Engl J Med.* 2019;380:1706–1715.

18. Abdelghani M, Mankerious N, Allali A, et al. Bioprosthetic valve performance after transcatheter aortic valve replacement with self-expanding versus balloon-expandable valves in large versus small aortic valve annuli: insights from the CHOICE Trial and the CHOICE-Extend Registry. *JACC Cardiovasc Interv.* 2018;11:2507-2518.

19. Regazzoli D, Chiarito M, Cannata F, et al. Transcatheter self-expandable valve implantation for aortic stenosis in small aortic annuli: The TAVI-SMALL Registry. *JACC Cardiovasc Interv*. 2020;13:196-206.

20. Mosteller RD. Simplified calculation of body-surface area. *N Engl J Med.* 1987;317:1098.

21. Chaker Z, Badhwar V, Alqahtani F, et al. Sex differences in the utilization and outcomes of surgical aortic valve replacement for severe aortic stenosis. *J Am Heart Assoc.* 2017;6.

22. López-de-Andrés A, Méndez-Bailón M, Perez-Farinos N, et al. Gender differences in incidence and in-hospital outcomes of surgical aortic valve replacement in Spain, 2001-15. *Eur J Public Health.* 2019;29:674–680.

23. Erinne I, Hiltner E, Bhasin V, et al. Sex disparities in the treatment of aortic stenosis and related outcomes: an analysis of the National Inpatient Sample. *Cardiology.* 2022;147:557–565.

24. Kaier K, von Zur Mühlen C, Zirlik A, et al. Sex-specific differences in outcome of transcatheter or surgical aortic valve replacement. *Can J Cardiol.* 2018;34:992–998.

25. Panoulas VF, Francis DP, Ruparelia N, et al. Female-specific survival advantage from transcatheter aortic valve implantation over surgical aortic valve replacement: Meta-analysis of the gender subgroups of randomised controlled trials including 3758 patients. *Int J Cardiol.* 2018;250:66–72.

26. Leon MB, Mack MJ, Hahn RT, Thourani VH, Makkar R, Kodali SK, Alu MC, Madhavan

MV, Chau KH, Russo M, Kapadia SR, Malaisrie SC, et al. Outcomes 2 years after transcatheter aortic valve replacement in patients at low surgical risk. *J Am Coll Cardiol.* 2021;77:1149-1161.

27. Forrest JK, Deeb GM, Yakubov SJ, et al. 3-Year outcomes after transcatheter or surgical aortic valve replacement in low-risk patients with aortic stenosis. J Am Coll Cardiol 2023;81:1663-1674.

28. Kulik A, Al-Saigh M, Chan V, et al. Enlargement of the small aortic root during aortic valve replacement: is there a benefit? *Ann Thorac Surg*. 2008;85:94–100.

29. Kimura S, Ushijima T, Fujita S, Sonoda H, Oishi Y, Tanoue Y, Shiose A. Efficacy of preoperative electrocardiographic-gated computed tomography in predicting the accurate aortic annulus diameter in surgical aortic valve replacement. *Gen Thorac Cardiovasc Surg.* 2021;69:466-471.

30. Tully A, Tom S, Xie J, O'Brian C, Gleason P, Grubb KJ. Evolving computed tomography angiography for aortic valve replacement: Optimizing transcatheter and surgical therapies. *J Card Surg.* 2022;37:4124-4133.

31. Fiore A, Gueldich M, Folliguet T. Sutureless valves fit/perform well in a small aortic annulus.

Fiore A, Gueldich M, Folliguet T. *Ann Cardiothorac Surg.* 2020;9:414-416.

32. Thorp SD, Khazaal J, Yu G, Parker JL, Timek TA. Magna ease bioprosthetic aortic valve: mid-term haemodynamic outcomes in 1126 patients. *Interact Cardiovasc Thorac Surg*. 2021;32:839-845.

33. Ghoneim A, Bouhout I, Demers P, Mazine A, et al. Management of small aortic annulus in the era of sutureless valves: A comparative study among different biological options. *J Thorac Cardiovasc Surg*. 2016 ;152:1019-1028.

34. Montero-Cruces L, Carnero-Alcázar M, Reguillo-Lacruz FJ, et al. One-year hemodynamic performance of three cardiac aortic bioprostheses: a randomized comparative clinical trial. *J Clin Med*. 2021;10:5340.

35. Zoghbi WA, Asch FM, Bruce C, et al. Guidelines for the Evaluation of Valvular Regurgitation After Percutaneous Valve Repair or Replacement. *J Am Soc Echocardiogr*. 2019; 32:431-475. .

36. Tirado-Conte G, Rodés-Cabau J, Oteo JF, et al. Transcatheter aortic valve implantation in patients with extra-small aortic annuli. *EuroIntervention* 2023;19:e340-e351.

FIGURE LEGENDS

Figure 1. Time-to-event curves at 2-year follow-up for mortality (**A**), stroke (**B**), cardiac rehospitalization (**C**), and the combined endpoint (**D**).

Figure 2. Changes in valve hemodynamics (aortic valve area, mean transvalvular gradient) (**A**), NYHA class (**B**), and quality of life parameters (**C**) over time.

Table 1. Baseline Characteristics of the Study Population.

	TAVR (n=77)	**SAVR (n=74)**
Clinical characteristics		
Age, years	75.9±5.3	75.1±4.9
Women	73 (94.8%)	67 (90.5%)
BMI, kg/m^2	27.7±5.1	28.7±5.4
BSA, m^2	1.69±0.18	1.73±0.19
NYHA class III-IV	23 (29.9%)	24 (32.4%)
STS, %	2.55 (1.79-3.27)	2.43 (1.67-3.31)
Diabetes	23 (29.9%)	22 (29.7%)
Hypertension	62 (80.5%)	61 (82.4%)
Atrial fibrillation	6 (7.8%)	14 (18.9%)
Renal insufficiency*	25 (32.5%)	26 (35.1%)
COPD	7 (9.1%)	14 (18.9%)
Coronary artery disease**	17 (22.1%)	14 (18.9%)
Prior pacemaker	2 (2.6%)	2 (2.7%)
Mean aortic annulus diameter (computed tomography), mm	21.2±1.2	21.1±1.2
Minimal aortic annulus diameter (computed tomography), mm	18.7±1.5	18.4±1.6
Aortic annulus area (computed tomography), mm^2	348±42	343±39
Aortic annulus perimeter (computed tomography), mm	67.3±5.0	66.3±6.3
Echocardiographic data		
Left ventricular ejection fraction, %	62±7	62±8
Mean aortic gradient, mm Hg	47±17	49±17
Maximal aortic gradient, mm Hg	79±24	80±24

Aortic valve area, cm^2	0.67±0.18	0.74±0.36
Moderate-severe aortic insufficiency¶	3/76 (4.0%)	6/71 (8.5%)
Procedural characteristics		
Approach		
Transfemoral	69/76 (90.8%)	-
Transcarotid/transaortic	7/76 (9.2%)	-
Valve type		
Balloon-expandable	31/76 (40.8%)	-
Self-expandable	45/76 (59.2%)	-
Stented (surgical)	-	56/71 (78.9%)
Sutureless (surgical)	-	15/71 (21.1%)
Aortic root enlargement	-	5/71 (7.0%)
PCI (preprocedure or at the time of TAVR) or CABG (at the time of SAVR)	10/76 (13.2%)	5/72 (6.9%)
Successful valve implantation	77 (100%)	74 (100%)
Need for a second valve	1 (1.3%)	-
Coronary obstruction	0 (0%)	1 (1.4%)
Cardiac tamponade	1 (1.3%)	4 (5.6%)
Annulus rupture	1 (1.3%)	-

*eGFR<60 ml/min/m^2 **Presence of significant coronary lesions (≥70% diameter stenosis) requiring treatment or prior CABG/PCI ¶The suboptimal quality of echocardiographic images precluded any evaluation of aortic regurgitation in 4 patients (1 TAVR group, 3 SAVR group)

Values are expressed as mean±SD, n (%) or median interquartile range; STS= Society of Thoracic Surgeons predicted risk of mortality;

Table 2. 30-day and Late Follow-up Outcomes.

	TAVR (n= 77)	SAVR (n= 74)	Difference TAVR-SAVR (95%CI)	P Value
	% of patient		Percentage points	
30-day outcomes				
Death	1 (1.3%)	1 (1.4%)	0.05 (-6.3 to 5.9)	1.000
Stroke	0 (0%)	2 (2.7%)	-2.7 (-9.4 to 2.3)	0.239
Disabling stroke	0 (0%)	2 (2.7%)	-2.7 (-9.4 to 2.3)	0.239
Death or stroke	1 (1.3%)	3 (4.1%)	-2.8 (-10.4 to 3.5)	0.360
Major/life-threatening bleeding	6 (7.8%)	16 (21.6%)	-13.8 (-26.0 to -2.1)	0.021
Myocardial infarction	2 (2.6%)	3 (4.1%)	-1.5 (-9.4 to 5.5)	0.677
New-onset atrial fibrillation	5 (6.5%)	20 (27.0 %)	-20.5 (-32.8 to -7.3)	<0.001
New-onset left bundle branch block	9 (11.7%)	3 (4.1%)	7.6 (-1.5 to 17.4)	0.131
New permanent pacemaker	9 (11.7%)	4 (5.4 %)	6.3 (-3.1 to 16.3)	0.247
Aortic valve reintervention	2 (2.6%)	0 (0 %)	2.6 (-2.8 to 9.4)	0.497
Follow-up outcomes (median: 2 [1-4] years)				
Death	7 (9.1%)	6 (8.1%)	1.0 (-9.0 to 10.8)	1.000
Stroke	3 (3.9%)	3 (4.1%)	-0.2 (-8.1 to 7.5)	1.000
Disabling stroke	0 (0%)	3 (4.1%)	-4.1 (-11.5 to 1.0)	0.115
Death or stroke	7 (9.1%)	8 (10.8)	-1.7 (-12.2 to 8.5)	0.790
Myocardial infarction	2 (2.6%)	3 (4.1%)	-1.5 (-9.4 to 5.5)	0.677
Major/life-threatening bleeding	10 (13.0%)	18 (24.3%)	-11.3 (-24.2 to 1.5)	0.094
New-onset atrial fibrillation	8 (10.4%)	23 (31.1%)	-20.7 (-33.9 to -6.3)	0.002
Permanent pacemaker	11 (14.3%)	5 (6.8 %)	-7.5 (-2.8 to 18.5)	0.187
Infective endocarditis	0 (0%)	2 (2.7%)	-2.7 (-9.4 to 2.3)	0.239
Aortic valve reintervention	2 (2.6%)	1 (1.4%)	1.3 (-5.2 to 8.1)	1.000
Cardiac rehospitalization	15 (19.5%)	15 (20.3%)	-0.8 (-14.0 to 12.3)	1.000
Heart failure rehospitalization	4 (5.2%)	6 (8.1%)	-2.9 (-12.3 to 5.8)	0.528

Table 3. 60-day Echocardiographic Findings.

	TAVR n=76	**SAVR N=72**	**Difference TAVR-SAVR (95%CI)**	**P value**
LVEF, %	61±6	61±8	0.3 (-2.3 to 2.9)	0.817
Stroke volume index, ml/m^2	75±18	74±21	1.9 (-4.6 to 8.4)	0.565
Mean aortic gradient, mmHg	11±5	11±5	0.3 (-1.3 to 1.9)	0.704
Mean gradient >20 mmHg	4 (5.3%)	7 (9.7%)	-5.0 (-13.8 to 3.9)	0.301
Maximal aortic gradient, mmHg	22±9	21±9	0.7 (-2.2 to 3.6)	0.653
Effective orifice area, cm^2	1.63±-.40	1.65±0.45	-0.02 (-0.16 to 0.12)	0.789
Effective orifice area indexed, cm^2/m^2	0.99±0.28	0.98±0.27	0.01 (-0.08 to 0.11)	0.755
Velocity ratio	0.50±0.11	0.50±0.11	0.00 (-0.03 to 0.04)	0.811
Stroke volume indexed, ml/m^2	46±11	43±12	2.2 (-1.8 to 6.2)	0.811
Severe PPM or moderate-severe AR (*Primary Endpoint*)	4/72 (5.6%)	7/68 (10.3%)	-4.7 (-13.7 to 4.2)	0.298
Aortic regurgitation*			-	0.475
None-trace	62/75 (83.7%)	59/70 (84.3%)		
Mild	13/75	9/70 (12.9%)		
Moderate/Severe	0/75 (0%)	0/70 (0%)		
PPM (severe) VARC-2**	4/72 (5.6%)	7/68 (10.3%)	-4.7 (-13.7 to 4.2)	0.298
PPM (severe) VARC-3	3/72 (4.2%)	5/68 (7.4%)	-3.2 (-10.9 to 4.6)	0.485

*The suboptimal quality of echocardiographic images precluded any evaluation of aortic regurgitation in 3 patients (1 TAVR and 2 SAVR group)
**The suboptimal quality of echocardiographic images precluded the evaluation of EOA (and subsequently the calculation of PPM) in 8 patients (4 patients in each group).
Values are expressed as mean±SD, n (%)
LVEF= left ventricular ejection fraction; PPM= prosthesis-patient mismatch.


A
Death
log-rank: p=0.974
Months
Number at Risk
SAVR 74 73 65 65 64 60 51 49 48 43
TAVR 77 76 67 64 63 62 57 55 55 45
B
Stroke
log-rank: p=0.591
Months
Number at Risk
SAVR 74 71 63 63 62 58 50 48 47 42
TAVR 77 76 67 64 63 62 56 53 53 44
C
Cardiac Hospitalization
log-rank: p=0.644
Months
Number at Risk
SAVR 74 68 55 54 53 50 42 40 39 35
TAVR 77 75 61 58 58 56 50 48 48 39
D
Death,Stroke or Cardiac Hospitalization
log-rank: p=0.388
Months
Number at Risk
SAVR 74 66 54 53 52 49 42 40 39 35
TAVR 77 75 61 58 58 56 50 48 48 38


A
P= 0.736
P= 0.001
P= 0.567
P= 0.376
Percentage of Patients
100
90
80
70
60
50
40
30
20
10
0
70,1
67,6
97,4
80,8
91,4
88,1
89,1
83.0
Baseline
30 Days
1 Year
2 Years
No. of Observations
77
74
76
73
58
59
55
47


B
KCCQ Overall Summary Score
P= 0.806
P= 0.004
P= 0.288
P= 0.437
100
90
80
70
60
85
84
83
80
80
65
76
64
TAVR
SAVR
Baseline
30 days
1 Year
2 Years
Mean Absolute Change from Baseline (%)
P= 0.011
P= 0.406
P= 0.821
17,9
11,1
17,5
17,7
15,7
17,2
30 days
1 Year
2 Years


C
AV Mean Gradient (mm Hg)
60
50
40
30
20
10
0
52
49
1.7
1.5
1.5
1.6
1.4
1.4
13
13
13
0.7
0.7
12
12
13
TAVR
SAVR
AV Orifice Area (cm²)
2
1,8
1,6
1,4
1,2
1
0,8
0,6
Baseline
30 Days
1 Year
2 Years